Non-peptide GnRH antagonists

US7365065B2 · kind B2 · utility

Assignee

• Ferring B.V. · NL

Inventors

• Michael Bryan Roe · Slough, GB
• Andrzej Roman Batt · Southampton, GB
• David Michael Evans · Royston, GB
• Gary Robert William Pitt · Melbourne, AU
• David Philip Rooker · Salisbury, GB

Key dates

• Filing date: Mar 12, 2003
• Grant date: Apr 29, 2008
• Expiry date: Dec 6, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds according to general formula 1, wherein A1-A3 are selected from A5 and A6 where A5 is either ═CR13— or ═N— and A6 is —NR14—, —O— or —S—; A4 is either a covalent bond or A5, provided that when A4 is a covalent bond one of A1-A3 must be A6 and the other two must be A5 and when A4 is A5 then all of A1-A3 must be A5; R1 is selected from H, NHY′ and COY2, in which case R2 is H, or R1 and R2 may both be methyl or together represent ═O; R3, R4 and R5 are each independently selected from H and lower alkyl groups; R6, R7, R8, R9, R10, R11 and R12 are each independently selected from H, lower alkyl groups, NH2, halogens (F, Cl and Br) O-alkyl, CH2NM2 and CF3; R13 is selected from H, F, Cl Br, NO2, NH2, OH, Me, Et, OMe, NMe2 and CF3; R14 is selected from H, methyl and ethyl; W is selected from ═CH— and ═N—; X is selected from CH2, O, S, SO2, NH and N lower alkyl; Y1 is selected from CO-lower alkyl, CO(CH2)bY3, CO(CH2)bCOY3 and CO(CH)NHCOY3, where b is 1-3; Y2 is selected from OR15, NR16R17 and NH(CH2)CCOY3, where c is 1-3; Y3 is selected from OR15 and NR16R17; R15 is selected from H, lower alkyl and (CH2)aR16, where a is 0-4; R16 and R17 are each independently selected from H, lower…